A Phase 1 randomized, double-blind study to investigate the single and multiple dose safety, tolerability and pharmacokinetics of WCK 4282 (FEP-TAZ) upon intravenous administrations in healthy volunteers

Completed

• Conditions: Bacterial infections; 10004018

• Registration Number: NL-OMON43462
• Lead Sponsor: Wockhardt Bio AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 55

Inclusion Criteria

Healthy Male or female, between 18 and 65 years of age both (inclusive)

Exclusion Criteria

Clinical significant abnormalities at medical research.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety, tolerability and pharmacokinetics.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.A.</p><br>